Alnylam Pharmaceuticals said that it has expanded its management team to include two new vice presidents and a CSO.
Kenneth Koblan, who has been named CSO, previously held various positions within Merck Research Laboratories, most recently vice president and site head of Rahway Basic Research. He holds a PhD in biochemistry from Johns Hopkins University.
Alnylam's previous CSO, John Schmidt, left the company in August of 2009.
The company also said that it has appointed Steven Bossone as its vice president of intellectual property and Garvin Warner as its vice president of preclinical development.
Bossone previously served as senior patent attorney at Shire, and had worked as a scientist in the oncology group of Millennium Pharmaceuticals. Warner previously served as assistant vice president and therapeutic area head in drug safety and metabolism at Genetics Institute/Wyeth.